Literature DB >> 7818806

Indirect costs of HIV/AIDS mortality in Canada.

R A Hanvelt1, N S Ruedy, R S Hogg, S Strathdee, J S Montaner, M V O'Shaughnessy, M T Schechter.   

Abstract

OBJECTIVE: To estimate and compare the societal impact of HIV infection and AIDS with other selected causes of male mortality in terms of the indirect costs of future production lost.
DESIGN: Descriptive, population-based economic evaluation study. PATIENTS: All men aged 25-64 years for whom HIV/AIDS or another selected disease was listed as the underlying cause of death in Canada from 1987 to 1991, as reported to Statistics Canada.
SETTING: Canada. MAIN OUTCOME MEASURES: Present value of future earnings lost for men using a human capital approach based on potential years of life lost in men aged 25-64 years.
RESULTS: Assuming a 2% annual growth in earnings and a 3% annual real discount rate, the present value of the total loss of future production for all men aged 25-64 years who died in Canada during 1987-1991 was estimated to be 39.74 billion 1990 US$. Deaths due to HIV/AIDS accounted for 5.3% of this total loss or 2.11 billion in 1990 US$. Future production loss due to HIV/AIDS more than doubled during the period from 1987 to 1991, from 0.27 to 0.60 billion 1990 US$. The loss in future earnings attributable to HIV/AIDS was exceeded only by that of ischaemic heart disease (15.2%), suicide (9.4%), motor vehicle accidents (6.6%), and lung cancer (6.6%). In total, these five causes of death accounted for 43.1% of the total indirect cost of production lost for men aged 25-64 years during the 5-year period.
CONCLUSION: Our findings demonstrated HIV/AIDS mortality is already having a dramatic impact on future wealth production in Canada. If the past trend continues, the production lost in 1994 should exceed 0.86 billion 1990 US$ and will account for more than 10% of the total annual loss for men aged 25-64 years.

Entities:  

Mesh:

Year:  1994        PMID: 7818806     DOI: 10.1097/00002030-199410000-00001

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  6 in total

1.  Social costs of untreated opioid dependence.

Authors:  R Wall; J Rehm; B Fischer; B Brands; L Gliksman; J Stewart; W Medved; J Blake
Journal:  J Urban Health       Date:  2000-12       Impact factor: 3.671

Review 2.  The impact of disease stage on direct medical costs of HIV management: a review of the international literature.

Authors:  Adrian Levy; Karissa Johnston; Lieven Annemans; Andrea Tramarin; Julio Montaner
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  Needle exchange programs: an economic evaluation of a local experience.

Authors:  M Gold; A Gafni; P Nelligan; P Millson
Journal:  CMAJ       Date:  1997-08-01       Impact factor: 8.262

Review 4.  Economic costs to business of the HIV/AIDS epidemic.

Authors:  Gordon G Liu; Jeff J Guo; Scott R Smith
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

5.  A multicentre study of patient survival, disability, quality of life and cost of care: among patients with AIDS in northern Italy.

Authors:  Andrea Tramarin; Stefano Campostrini; Maarten J Postma; Guido Calleri; Keith Tolley; Nicoletta Parise; Fausto de Lalla
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

6.  The Direct Medical Costs of Late Presentation (<350/mm) of HIV Infection over a 15-Year Period.

Authors:  Hartmut B Krentz; M John Gill
Journal:  AIDS Res Treat       Date:  2011-08-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.